Progress in Pancreatic Cancer Treatment with New Drug

A new medication, daraxonrasib, offers hope for those suffering from advanced pancreatic cancer. Researchers presented their findings at the American Society for Clinical Oncology meeting in Chicago, showing promising results.

Improved Survival Rates

Patients who took daraxonrasib nearly doubled their survival time compared to those on standard chemotherapy. Study participants lived a median of 13.2 months on the drug, while those using chemotherapy lived a median of 6.7 months. Though not a cure, this represents a significant improvement.

“While not curing the cancer, it is a very large step forward,” said Dr. Zev Wainberg from UCLA, a lead researcher in the study.

Daraxonrasib targets a mutated protein linked to more than 90% of pancreatic cancer cases. Traditional treatments had failed to address this protein.

Quality of Life Enhancement

Patients reported fewer severe side effects and improved quality of life while using the drug. The treatment reduced pain and allowed for longer usage compared to chemotherapy, with some patients continuing its use beyond the study’s conclusion.

Dr. Rachna Shroff from the University of Arizona Cancer Center expressed emotion seeing the benefits for patients, citing the durable and meaningful results as encouraging.

Potential New Standard of Care

Dr. Brian Wolpin of the Dana-Farber Cancer Institute believes daraxonrasib should become a standard treatment for metastatic pancreatic cancer cases. There are plans to study its use earlier in the disease progression and potentially aid in surgical eligibility.

Despite concerns about side effects such as severe rashes and mouth sores, many believe the benefits outweigh the drawbacks.

Future Prospects

The FDA plans to expedite the drug’s review, and it has gained attention as a viable option for patients with few alternatives. Former U.S. Sen. Ben Sasse highlighted its pain-relief benefits on “60 Minutes,” spurring demand.

Researchers have high hopes, with dozens of experimental drugs in the pipeline. Pancreatic cancer remains a challenge due to its late detection and aggressive nature, with an overall 13% five-year survival rate, according to the American Cancer Society.

Targeting KRAS Mutations

The new drug targets KRAS gene mutations, a key driver in cancer growth, using a molecular glue-like approach. Historically, these mutations were considered difficult to treat, but daraxonrasib offers a groundbreaking method of addressing them.

“This thing works drastically differently,” said Dr. Andrew Coveler from the Fred Hutchinson Cancer Center.

The innovation may pave the way for more therapeutic options, including vaccines aimed at preventing recurrence post-surgery.

The Associated Press Health and Science Department receives support from Howard Hughes Medical Institute and the Robert Wood Johnson Foundation but maintains editorial control over the content.